nexviadyme
sanofi b.v. - avalglucosidase alfa - ii típusú glikogén-tároló betegség - egyéb táplálkozási traktus pedig anyagcsere termékek, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).
xenpozyme
sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - egyéb táplálkozási traktus pedig anyagcsere termékek, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.
aubagio
sanofi winthrop industrie - teriflunomide - szklerózis multiplex - szelektív immunszuppresszánsok - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
co-amilozid 5/50 tabletta
sanofi-synthélabo rt. - amiloride; hydrochlorothiazide -
diclofenac-chinoin sr 75 mg retard filmtabletta
sanofi-synthélabo rt. - a diclofenac -
diclofenac-chinoin sr 100 mg retard filmtabletta
sanofi-synthélabo rt. - a diclofenac -
algomen 250 mg kapszula
sanofi-synthélabo rt. - mefenamic acid -
algomen 500 mg filmtabletta
sanofi-synthélabo rt. - mefenamic acid -
aciclosan 200 mg tabletta
sanofi-synthélabo rt. - aciklovir -
aciclosan 400 mg tabletta
sanofi-synthélabo rt. - aciklovir -